All News

1200 PsA pts 6 countries IL17is as effective as TNFi and JAK despite more failed bDMARDs and monotherapy & faster onset action than IL23s ⁦@RheumNow⁩ #EULAR2024 https://t.co/SM5CA7KUvd

Links:

Peter Nash drpnash ( View Tweet)
#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar ACR30 response rates at Wk16 (IXE=89%; ADA=95%). Open label and long-term follow up for IXE is ongoing to assess for sustainment @RheumNow https://t.co/lk42I7Mn8B

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
New reccs for knee/hip #OA w/2 overarching principles 1. Biopsychosocial approach 2.Individualized Rx w/shared decision making (includes education, diet/exercise, healthy weight, appropriate assistive device/footware, modify work factors, pain coping skills) #EULAR24 @rheumnow https://t.co/0LVLBMGO7L

Links:

TheDaoIndex KDAO2011 ( View Tweet)
Different pathways of auto inflammatory disease which is an amplifier system. Always check the phenotype first before genotype. Kasner D #EULAR2024 @RheumNow https://t.co/MtPzsVBNjn

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
#EULAR2024 LBA0010 Promising Tx with diff mode of action in antibody+ #Sjogren. Phase 2 RCT Nipocalimab, anti-neonatal Fc receptor (FcRn)Ab that reduces IgG, met primary endpoint (clinESSDAI). Low SIE but doubled in lowest dose vs PBO (unrelated to IgG). On to Phase3 @RheumNow https://t.co/NlCc2l4zFL

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 LBA0007 More evidence on deep Bcell depletion in #lupus. Open label trial of Daratumumab, anti-CD38 plasma cell Ab showed rapid reduction in biomarker endpoint, dsDNA, as well as SRI-4 & CLASI-A at Wk12. No SAE but longer F/U needed since IgG reduced by 6g/L @RheumNow https://t.co/IIFPYV9oIr

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2024 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

Thanks for these updates recommendations for hip/knee OA -- but, still not much has changed. #eular2034 https://t.co/NMwFWxwocF
Dr. John Cush RheumNow ( View Tweet)
The Role of Psychosocial Determinants in the Management of RA Dr. Mrinalini Dey reports from Eular 2024 in Vienna, Austria about an abstract she will present during the meeting, POS0309. https://t.co/o3vqHJnQHz https://t.co/ibMrNNCmUr

Links:

Dr. John Cush RheumNow ( View Tweet)
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis? Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at #EULAR2024 in Vienna, Austria: OP0195 LBA0005 POS0803 OP0138 https://t.co/MnefRxYqMh https://t.co/Mwq4s7eTKY

Links:

Dr. John Cush RheumNow ( View Tweet)
AI meets Rheumatology: ChatGPT and patient response optimization Large language models like ChatGPT, trained on vast text data, are revolutionizing healthcare by understanding and generating human-like language. https://t.co/GzT9UvndTX https://t.co/ziOh8oCbZ9

Links:

Dr. John Cush RheumNow ( View Tweet)
A beautiful free concert in Vienna #EULAR2024 ⁦@eular_org⁩ ⁦@RheumNow⁩ https://t.co/8YPWbkmTUr

Links:

Janet Pope Janetbirdope ( View Tweet)
@RheumNow The always erudite @LCalabreseDO is no slouch of a debating opponent, however. He acknowledges that the science has been imperfect, too much is wrapped up in it, and that fibromyalgia can teach a lot to long COVID. #EULAR2024 @RheumNow https://t.co/TzR4SMZh9f

Links:

David Liew drdavidliew ( View Tweet)
@RheumNow @LCalabreseDO @NIH and Len gives us some key recommendations for better practice for long COVID - for me, equally as applicable to fibromyalgia as to long COVID. Fantastic discussion #EULAR2024 @RheumNow https://t.co/8PnjPEKcOu

Links:

David Liew drdavidliew ( View Tweet)
😂😂😂I love this study so much. I guess , happy people live better. #Eular2024 https://t.co/ChrdSgw51k

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)

#IgG4 Pearls Thanks for sharing Isolated ⬆️ serum #IgG4 level ✅ How high? 5x ULN ➡️ PPV 75% ✅Typical organ(s) involved? ❓Another explanation Dr Jone Stone #Rheumatology #EULAR2024 https://t.co/UVKmH57iVM https://t.co/uxHBl0I3cM

Links:

Ask The Rheumatologist LastManStand85 ( View Tweet)
EULAR guidelines for screening for TB in rheumatic disease patients #EULAR2024 https://t.co/jaixl8lGkY

Links:

Jilaine Bolek Berquist BolekBerqui ( View Tweet)
Setting a standard for imaging reporting in patients with suspected axial spondyloarthritis is an important part of our efforts toward improving the early and accurate diagnosis of SpA: https://t.co/zYbcL1CaTP https://t.co/1jnBDBSDNv

Links:

Prof. Denis Poddubnyy DrPoddubnyy ( View Tweet)
NEW biomarkers in #MAS 1️⃣ IL-18 (available at some 🏥)⭐️ 2️⃣ S100A12 3️⃣ CXCL9/10 🚨When suspecting #MAS, don’t ignore the possibility of a monogenic disorder! 🎙️ Dr. Sophie Georgin-Lavialle 🇫🇷 #macrophage #EULAR2024 #genetics #rheumx https://t.co/Uot3JjrWs8

Links:

Artem Minalyan, MD, DABOM AMinalyan ( View Tweet)
DMOADs in #osteoarthritis at #EULAR2024: 1) Tonia Vincent: StepUp OA endotype SF proteomics —> endothelial to mesenchymal transition proteins. 2) Phil Conaghan: proregenerative (& degeneration slowing) therapies in pipeline. 3) @Larhumato: novel RCT designs & structure outcomes

Tuhina Neogi, MD, PhD Tuhina_Neogi ( View Tweet)

×